Phase-III Ophthalmic Study is Approved within 44 Working Days
The end of the year was marked for GCT team with yet another achievement.
Clinical trial approval was received ahead of official timelines for Phase III study,
– the whole review process, including Q/A with competent authority, lasted 44 working days.
January 10, 2019
End of enrollment for Phase II Ulcerative Colitis trial
Enrollment has just been accomplished for a study in patients with moderate to severe Ulcerative Colitis,
a global double-blind, placebo-controlled, parallel group multicenter study designed to evaluate the
safety profile of the investigational product.
December 27, 2018
2018 has come to the end, and we are glad to look back to what was achieved and to share GCT year in the Highlights!
We would like to thank our long-term partners for the credibility, trust and loyalty, and we hope for the new accomplishments together in the coming year!
December 25, 2018
Investigator meeting completed for Phase 1-2 study in adult participants with relapsed or refractory PTCL
This month GCT has successfully conducted Investigator’s meeting for the international multicenter Phase 1-2 study in adult participants with
relapsed or refractory Peripheral T Cell Lymphoma (PTCL). The study will be conducted across 17 study sites by GCT in the U.S., Russia and Ukraine.
November 30, 2018
Meet our clients
All trademarks, brand names and logotypes are intellectual property of their respective owners.
Austria Center Vienna, booth #B14
2019, February 5-7
Washington, DC, USA
2019, February 19-21
Centro de Congressos de Lisboa
2019, March 26-31
2019, April 6-9